193 related articles for article (PubMed ID: 30500985)
1. Systems analysis of phosphorylation-regulated Bcl-2 interactions establishes a model to reconcile the controversy over the significance of Bcl-2 phosphorylation.
Song T; Wang P; Yu X; Wang A; Chai G; Fan Y; Zhang Z
Br J Pharmacol; 2019 Feb; 176(3):491-504. PubMed ID: 30500985
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
[TBL] [Abstract][Full Text] [Related]
3. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
4. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
5. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
6. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
7. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
[TBL] [Abstract][Full Text] [Related]
8. Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1.
Guo Z; Song T; Xue Z; Liu P; Zhang M; Zhang X; Zhang Z
Eur J Pharm Sci; 2020 Jan; 142():105105. PubMed ID: 31669390
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance.
Dai H; Ding H; Meng XW; Lee SH; Schneider PA; Kaufmann SH
Cancer Res; 2013 Dec; 73(23):6998-7008. PubMed ID: 24097825
[TBL] [Abstract][Full Text] [Related]
10. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC
Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a small-molecule pBcl-2 inhibitor that overcomes pBcl-2-mediated resistance to apoptosis.
Song T; Yu X; Liu Y; Li X; Chai G; Zhang Z
Chembiochem; 2015 Mar; 16(5):757-65. PubMed ID: 25711460
[TBL] [Abstract][Full Text] [Related]
12. Expression and Solution NMR Study of Multi-site Phosphomimetic Mutant BCL-2 Protein.
Song T; Cao K; Fan YD; Zhang Z; Guo ZW; Zhang MH; Liu P
Protein Pept Lett; 2019 Jul; 26(6):449-457. PubMed ID: 30919764
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
14. Differential Expression of Bcl-2 Family Proteins Determines the Sensitivity of Human Follicular Lymphoma Cells to Dexamethasone-mediated and Anti-BCR-mediated Apoptosis.
Adem J; Ropponen A; Eeva J; Eray M; Nuutinen U; Pelkonen J
J Immunother; 2016 Jan; 39(1):8-14. PubMed ID: 26641257
[TBL] [Abstract][Full Text] [Related]
15. Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions.
Deng X; Gao F; Flagg T; May WS
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):153-8. PubMed ID: 14660795
[TBL] [Abstract][Full Text] [Related]
16. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
17. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
[TBL] [Abstract][Full Text] [Related]
18. Anti-apoptotic BCL-2 regulation by changes in dynamics of its long unstructured loop.
Lan YJ; Yeh PS; Kao TY; Lo YC; Sue SC; Chen YW; Hwang DW; Chiang YW
Commun Biol; 2020 Nov; 3(1):668. PubMed ID: 33184407
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.
Li X; Dou J; You Q; Jiang Z
Eur J Med Chem; 2021 Aug; 220():113539. PubMed ID: 34034128
[TBL] [Abstract][Full Text] [Related]
20. Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2.
Liu Y; Zhang Z; Song T; Liang F; Xie M; Sheng H
Br J Pharmacol; 2013 Aug; 169(7):1612-23. PubMed ID: 23651505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
